Zobrazeno 1 - 10 of 16 pro vyhledávání: '"Ágnes Benedict"'
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making
Autor: Nicholas Latimer, Ting-An Tai, Zsofia Kiss, Ágnes Benedict, Andreas Nikolaou
Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 24(4)
Objectives\ud This research aims to explore how often the National Institute for Health and Care Excellence (NICE) uses immature overall survival data to inform reimbursement decisions on cancer treatments, and the implications of this for resource a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a81bd38dbf8e5db3bcce834a509c3dca
https://pubmed.ncbi.nlm.nih.gov/33840428
Zobrazit plný text záznamu
4
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
Autor: Ivan Houisse, Sumeet Panjabi, Ágnes Benedict, Istvan Majer, Marco Campioni, Sikander Ailawadhi, Andrzej Jakubowiak
Publikováno v: Expert Review of Hematology. 10:1107-1119
We assessed the economic value of carfilzomib 56 mg/mCost-effectiveness of Kd56 vs. Vd was assessed using a partitioned survival model by estimating progression-free survival, overall survival, and direct costs over a lifetime horizon. Surveillance E
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a02b7c91c361b20b5481dfa789a11123
https://doi.org/10.1080/17474086.2017.1391088
Zobrazit plný text záznamu
5
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective
Autor: Sumeet Panjabi, Andrzej Jakubowiak, Eszter Tichy, Ivan Houisse, Marco Campioni, Sanjay K. Aggarwal, Beth Barber, Ágnes Benedict, Andromachi Giannopoulou
Publikováno v: Journal of Medical Economics. 19:1061-1074
To assess the economic value of carfilzomib (Kyprolis), this study developed the Kyprolis Global Economic Model (K-GEM), which examined from a United States (US) payer perspective the cost-effectiveness of carfilzomib-lenalidomide-dexamethasone (KRd)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdba37594228dd87a10897df8609e93b
https://doi.org/10.1080/13696998.2016.1194278
Zobrazit plný text záznamu
6
Akademický článek
A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan
Autor: Po‐Jung Su, Ying Xiao, Amy Y. Lin, Connie Goh, Ethan Wu, Kevin Liu, Patrick Chou, Kaitlin Kuo, Roberto Palencia, Jane Chang, Mairead Kearney, Venediktos Kapetanakis, Agnes Benedict
Publikováno v: Cancer Reports, Vol 6, Iss 10, Pp n/a-n/a (2023)
Abstract Background Patients with locally advanced or metastatic urothelial carcinoma have limited treatment options and a poor prognosis. The JAVELIN Bladder 100 trial showed that avelumab as first‐line maintenance plus best supportive care signif
Externí odkaz: https://doaj.org/article/2042b9fe238f47b3a68141f7b30dd0fb
Zobrazit plný text záznamu
8
INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES
Autor: Sonja V. Sorensen, Ágnes Benedict, Feng Pan, Kevin B. Knopf, Jo Wern Goh, Connie Chen, Denise A. Yardley, Miguel Martin, Shrividya Iyer, Carla Giorgetti
Publikováno v: International Journal of Technology Assessment in Health Care. 28:12-21
Objectives:This study aims to estimate the annual U.S. societal costs associated with treatment of metastatic breast cancer (MBC) patients using an incidence-based cost-of-illness (COI) framework.Methods:An incidence-based COI model was constructed i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79cefeb57812acbc258758a933c83048
https://doi.org/10.1017/s026646231100064x
Zobrazit plný text záznamu
9
An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK
Autor: Ágnes Benedict, David Cameron, Hélène Corson, Stephen E. Jones
Publikováno v: PharmacoEconomics. 27(10)
Paclitaxel and docetaxel have been available for the treatment of metastatic breast cancer (MBC) since the 1990s. However, until very recently, comparisons between these two drugs have been difficult due to lack of direct comparative clinical evidenc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e909c3d6a767b6c54190e5e5092a76eb
https://pubmed.ncbi.nlm.nih.gov/19803539
Zobrazit plný text záznamu
10
Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland
Autor: Jessamy Baird, Erwin De Cock, Ágnes Benedict, Jorge Arellano
Publikováno v: Journal of affective disorders. 120(1-3)
Background Major depressive disorders (MDD) are responsible for substantial direct and indirect health care costs. Despite the availability of numerous treatments, the need for effective pharmacotherapy remains. Duloxetine is a relatively balanced se
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a5133417fa05a6eb2c956fa6434513a
https://pubmed.ncbi.nlm.nih.gov/19497623
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje